4-(4-Methoxybenzyloxy)benzohydrazide | 147807-55-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-Methoxybenzyloxy)benzohydrazide
• 英文别名: 4-[(4-methoxyphenyl)methoxy]benzohydrazide
• CAS: 147807-55-4
• 化学式: C₁₅H₁₆N₂O₃
• 分子量: 272.304
• InChiKey: ZAAASMBNJMCCHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  73.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-Methoxybenzyloxy)benzohydrazide 以 乙醇 、 甲苯 为溶剂， 反应 51.0h， 生成 3-{5-[4-(4-Methoxy-benzyloxy)-phenyl]-2-oxo-[1,3,4]oxadiazol-3-yl}-propionitrile
  参考文献：
  名称：

  5-[4-(Benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogs: new reversible, highly potent, and selective monoamine oxidase type B inhibitors

  摘要：

  Thirty-three new 5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives including related analogues, designed as inhibitors of monoamine oxidase type B (MAO B), were synthesized and investigated both in vitro and ex vivo for their abilities to inhibit selectively rat brain MAO B over MAO A. Three inhibitors were found to act as reversible, highly potent, and selective MAO B inhibitors, namely the nitrile derivative 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-2(3H)-one (12a) and two closely related homologues, the corresponding oxadiazolethione 13a and the alcohol 14b. Their IC50(MAO B) values are in the low nanomolar range of 1.4-4.6 nM and their selectivities, estimated by the ratio of IC50 values (A/B), are from 3200 to >71 400. Compound 12a exhibited the highest activity against MAO B. Its IC50 was evaluated to be 1.4 nM with a quasitotal selectivity (>71 400) toward this enzyme. In ex vivo studies, 12a showed a reversible and short duration of action. MAO B was markedly inhibited with the oral dose of 1 mg/kg without any alteration of MAO A, and the inhibition almost did not exceed 24 h. Its ED50 (1 h after oral administration) was evaluated to be 0.56 mg (1.7 mumol)/kg. Remarkably, MAO A was not affected at doses as high as 1500 mg/kg, po. In addition, no apparent toxicity or behavioral anomaly was observed during the treatment even at the maximum administrated dose. SAR studies emphasize the existence of three binding sites to the enzyme with a special importance of the terminal phenyl. Analysis of the inhibition kinetics indicated that 12a acts in a two-step mechanism as a competitive, slow, and tight-binding inhibitor of MAO B with a K(i) value of 0.22 muM and an overall K(i)* value at equilibrium of 0.7 nM.

  DOI：

  10.1021/jm00061a006
• 作为产物：
  描述：

  过氧化氢酶 在 一水合肼 、 potassium hydroxide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 9.5h， 生成 4-(4-Methoxybenzyloxy)benzohydrazide
  参考文献：
  名称：

  Synthesis and Anticonvulsant Activity Evaluation of 4-butyl-5-(4- alkoxyphenyl)-2H-1,2,4-triazole-3(4H)-ones

  摘要：

  设计并合成了一系列4-丁基-5-(4-烷氧基苯基)-2H-1,2,4-三唑-3(4H)-酮(6a-6u)，并通过最大电击试验和旋转体试验评估了这些化合物的抗惊厥作用和神经毒性。在合成的化合物中，4-丁基-5-(4-(2-氟苄基)苯基)-2H-1,2,4-三唑-3 (4H)-酮（6k）的药效最强，ED50 值为 27.4 mg/kg，保护指数（PI = TD50/ED50）值为 12.0。除了抗 MES 的药效外，化合物 6k 对戊烯四唑（PTZ）、3-巯基丙酸（3-MP）和双谷氨酸（BIC）诱导的癫痫发作也有很强的抑制作用，这表明其抗惊厥活性可能涉及包括增强 GABA 能活性在内的作用机制。

  DOI：

  10.2174/1570180810666131122003939

文献信息

• SELECTIVE ANDROGEN RECEPTOR MODULATORS
  申请人：Miller Chris P.

  公开号：US20100041721A1

  公开（公告）日：2010-02-18

  This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig and intermediates useful in the preparation of same.

  本发明提供了I、Ia、Ib、Ic、Id、Ie、If或Ig的化合物或其盐，以及含有I、Ia、Ib、Ic、Id、Ie、If或Ig化合物和药用可接受的载体的药物组合物，调节雄激素受体的方法，治疗通过雄激素受体调节剂有益治疗的疾病的方法（例如肌肉萎缩、前列腺癌、避孕、2型糖尿病相关疾病或疾病、贫血、抑郁症和肾脏疾病），以及制备I、Ia、Ib、Ic、Id、Ie、If或Ig化合物的过程和制备中间体。
• Selective androgen receptor modulators
  申请人：Radius Health, Inc.

  公开号：US08268872B2

  公开（公告）日：2012-09-18

  This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig and intermediates useful in the preparation of same.

  本发明提供了I、Ia、Ib、Ic、Id、Ie、If或Ig的化合物或其盐，以及包含化合物I、Ia、Ib、Ic、Id、Ie、If或Ig和药用载体的制药组合物，调节雄激素受体的方法，治疗通过雄激素受体调节剂有益治疗的疾病的方法（例如肌肉萎缩、前列腺癌、避孕、与2型糖尿病相关的疾病或疾病、贫血、抑郁症和肾脏疾病）以及制备化合物I、Ia、Ib、Ic、Id、Ie、If或Ig的过程和制备同类中间体的方法。
• Selective Androgen Receptor Modulators
  申请人：Miller Chris P.

  公开号：US20130116288A1

  公开（公告）日：2013-05-09

  This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, If or Ig and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig and intermediates useful in the preparation of same.

  本发明提供了化合物I、Ia、Ib、Ic、Id、Ie、If或Ig或其盐，包括含有化合物I、Ia、Ib、Ic、Id、If或Ig和药用载体的制药组合物，改变雄激素受体的方法，治疗通过雄激素受体调节剂有益治疗的疾病的方法（如肌肉萎缩、前列腺癌、避孕、2型糖尿病相关疾病或疾病、贫血、抑郁症和肾脏疾病），以及制备化合物I、Ia、Ib、Ic、Id、Ie、If或Ig和制备同类中间体的过程。
• US8268872B2
  申请人：——

  公开号：US8268872B2

  公开（公告）日：2012-09-18
• US8629167B2
  申请人：——

  公开号：US8629167B2

  公开（公告）日：2014-01-14